U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Pazopanib response

MedGen UID:
851261
•Concept ID:
CN232333
•
Sign or Symptom
Drug:
Pazopanib
MedGen UID:
321830
•Concept ID:
C1831796
•
Pharmacologic Substance
A small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. Pazopanib selectively inhibits vascular endothelial growth factor receptors (VEGFR)-1, -2 and -3, c-kit and platelet derived growth factor receptor (PDGF-R), which may result in inhibition of angiogenesis in tumors in which these receptors are upregulated. [from NCI]
Pazopanib

Professional guidelines

PubMed

Systemic sarcoidosis during pazopanib treatment for clear cell renal cell carcinoma.
Vaccaro M, Borgia F, Lentini M, Gaeta M, MarafiotI I
Indian J Dermatol Venereol Leprol 2023 May-Jun;89(3):444-446. doi: 10.25259/IJDVL_599_2021. PMID: 36688889
Clinical treatment decisions for advanced renal cell cancer.
Choueiri TK
J Natl Compr Canc Netw 2013 May;11(5 Suppl):694-7. doi: 10.6004/jnccn.2013.0204. PMID: 23704246
Pazopanib and the treatment palette for soft-tissue sarcoma.
Bramwell VH
Lancet 2012 May 19;379(9829):1854-6. Epub 2012 May 16 doi: 10.1016/S0140-6736(12)60739-9. PMID: 22595798

Curated

DailyMed Drug Label, VOTRIENT- pazopanib hydrochloride tablet, 2021

Recent clinical studies

Etiology

Pazopanib pharmacokinetically guided dose optimization in three cancer patients with gastrointestinal resection.
Tardy C, Puszkiel A, Boudou-Rouquette P, De Percin S, Alexandre J, Berge M, Ulmann G, Blanchet B, Batista R, Goldwasser F, Thomas Schoemann A
Cancer Chemother Pharmacol 2024 Feb;93(2):169-175. Epub 2023 Aug 24 doi: 10.1007/s00280-023-04574-z. PMID: 37620675
PD-L1 tumour expression is predictive of pazopanib response in soft tissue sarcoma.
Kim SK, Kim JH, Kim SH, Lee YH, Han JW, Baek W, Woo HY, Jeon MK, Kim HS
BMC Cancer 2021 Mar 31;21(1):336. doi: 10.1186/s12885-021-08069-z. PMID: 33789622Free PMC Article
Pazopanib does not bring remarkable improvement in patients with angiosarcoma.
Kitamura S, Yanagi T, Inamura Y, Hata H, Imafuku K, Yoshino K, Shimizu H
J Dermatol 2017 Jan;44(1):64-67. Epub 2016 Aug 29 doi: 10.1111/1346-8138.13558. PMID: 27569550
TP53 mutational status is predictive of pazopanib response in advanced sarcomas.
Koehler K, Liebner D, Chen JL
Ann Oncol 2016 Mar;27(3):539-43. Epub 2015 Dec 8 doi: 10.1093/annonc/mdv598. PMID: 26646755Free PMC Article
Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: a Southern China Urology Cancer Consortium Trial.
Xie M, He CS, Huang JK, Lin QZ
Eur J Cancer 2015 Mar;51(5):595-603. Epub 2015 Jan 21 doi: 10.1016/j.ejca.2015.01.005. PMID: 25618828

Diagnosis

Pazopanib-induced changes in protein expression signatures of extracellular vesicles in synovial sarcoma.
Shiozawa K, Yoshioka Y, Qiao Z, Shuting J, Ochiya T, Kondo T
Biochem Biophys Res Commun 2018 Nov 30;506(3):723-730. Epub 2018 Oct 27 doi: 10.1016/j.bbrc.2018.10.012. PMID: 30454707

Therapy

Pazopanib pharmacokinetically guided dose optimization in three cancer patients with gastrointestinal resection.
Tardy C, Puszkiel A, Boudou-Rouquette P, De Percin S, Alexandre J, Berge M, Ulmann G, Blanchet B, Batista R, Goldwasser F, Thomas Schoemann A
Cancer Chemother Pharmacol 2024 Feb;93(2):169-175. Epub 2023 Aug 24 doi: 10.1007/s00280-023-04574-z. PMID: 37620675
PD-L1 tumour expression is predictive of pazopanib response in soft tissue sarcoma.
Kim SK, Kim JH, Kim SH, Lee YH, Han JW, Baek W, Woo HY, Jeon MK, Kim HS
BMC Cancer 2021 Mar 31;21(1):336. doi: 10.1186/s12885-021-08069-z. PMID: 33789622Free PMC Article
Neutrophil-to-lymphocyte ratio after pazopanib treatment predicts response in patients with advanced soft-tissue sarcoma.
Kobayashi H, Okuma T, Oka H, Hirai T, Ohki T, Ikegami M, Sawada R, Shinoda Y, Akiyama T, Sato K, Abe S, Kawano H, Goto T, Tanaka S
Int J Clin Oncol 2018 Apr;23(2):368-374. Epub 2017 Oct 31 doi: 10.1007/s10147-017-1199-6. PMID: 29086877
Pazopanib does not bring remarkable improvement in patients with angiosarcoma.
Kitamura S, Yanagi T, Inamura Y, Hata H, Imafuku K, Yoshino K, Shimizu H
J Dermatol 2017 Jan;44(1):64-67. Epub 2016 Aug 29 doi: 10.1111/1346-8138.13558. PMID: 27569550
TP53 mutational status is predictive of pazopanib response in advanced sarcomas.
Koehler K, Liebner D, Chen JL
Ann Oncol 2016 Mar;27(3):539-43. Epub 2015 Dec 8 doi: 10.1093/annonc/mdv598. PMID: 26646755Free PMC Article

Prognosis

PD-L1 tumour expression is predictive of pazopanib response in soft tissue sarcoma.
Kim SK, Kim JH, Kim SH, Lee YH, Han JW, Baek W, Woo HY, Jeon MK, Kim HS
BMC Cancer 2021 Mar 31;21(1):336. doi: 10.1186/s12885-021-08069-z. PMID: 33789622Free PMC Article
Neutrophil-to-lymphocyte ratio after pazopanib treatment predicts response in patients with advanced soft-tissue sarcoma.
Kobayashi H, Okuma T, Oka H, Hirai T, Ohki T, Ikegami M, Sawada R, Shinoda Y, Akiyama T, Sato K, Abe S, Kawano H, Goto T, Tanaka S
Int J Clin Oncol 2018 Apr;23(2):368-374. Epub 2017 Oct 31 doi: 10.1007/s10147-017-1199-6. PMID: 29086877
TP53 mutational status is predictive of pazopanib response in advanced sarcomas.
Koehler K, Liebner D, Chen JL
Ann Oncol 2016 Mar;27(3):539-43. Epub 2015 Dec 8 doi: 10.1093/annonc/mdv598. PMID: 26646755Free PMC Article

Clinical prediction guides

Pazopanib pharmacokinetically guided dose optimization in three cancer patients with gastrointestinal resection.
Tardy C, Puszkiel A, Boudou-Rouquette P, De Percin S, Alexandre J, Berge M, Ulmann G, Blanchet B, Batista R, Goldwasser F, Thomas Schoemann A
Cancer Chemother Pharmacol 2024 Feb;93(2):169-175. Epub 2023 Aug 24 doi: 10.1007/s00280-023-04574-z. PMID: 37620675
PD-L1 tumour expression is predictive of pazopanib response in soft tissue sarcoma.
Kim SK, Kim JH, Kim SH, Lee YH, Han JW, Baek W, Woo HY, Jeon MK, Kim HS
BMC Cancer 2021 Mar 31;21(1):336. doi: 10.1186/s12885-021-08069-z. PMID: 33789622Free PMC Article
Neutrophil-to-lymphocyte ratio after pazopanib treatment predicts response in patients with advanced soft-tissue sarcoma.
Kobayashi H, Okuma T, Oka H, Hirai T, Ohki T, Ikegami M, Sawada R, Shinoda Y, Akiyama T, Sato K, Abe S, Kawano H, Goto T, Tanaka S
Int J Clin Oncol 2018 Apr;23(2):368-374. Epub 2017 Oct 31 doi: 10.1007/s10147-017-1199-6. PMID: 29086877
TP53 mutational status is predictive of pazopanib response in advanced sarcomas.
Koehler K, Liebner D, Chen JL
Ann Oncol 2016 Mar;27(3):539-43. Epub 2015 Dec 8 doi: 10.1093/annonc/mdv598. PMID: 26646755Free PMC Article
Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: a Southern China Urology Cancer Consortium Trial.
Xie M, He CS, Huang JK, Lin QZ
Eur J Cancer 2015 Mar;51(5):595-603. Epub 2015 Jan 21 doi: 10.1016/j.ejca.2015.01.005. PMID: 25618828

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Curated

    Consumer resources

    Reviews

    Related information

    • ClinVar
      Related medical variations
    • GTR
      Related information in GTR
    • GTR(Clinical)
      Clinical tests in GTR
    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...